Physician
Rachel C. King MD PA
Rachel C. King MD PA was paid $1.63M by Medicaid between Jan 2018 and Dec 2024, across 54 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 36% of everything it billed.
33Billing provider infoRACHEL C. KING MD PA
ASHDOWN, AR 71822
ASHDOWN, AR 71822
33aNPI1598191850assigned 09/18/2013
33bProvider typeInternal Medicine Physician
28Total paid$1.63M
24GClaims50,652
24DCodes billed54
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Internal Medicine Physician providers in Arkansas
Rank by total paid#9 of 117
Median peer was paid$44K
This provider vs. median37×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 6,464 | $186K | |
| 2019 | 8,646 | $261K | |
| 2020 | 7,498 | $234K | |
| 2021 | 6,886 | $235K | |
| 2022 | 6,967 | $248K | |
| 2023 | 7,466 | $245K | |
| 2024incomplete | 6,725 | $226K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 36% | 18,328 | 15,723 | $594K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 10% | 3,375 | 3,109 | $164K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 9.8% | 3,098 | 2,893 | $160K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.9% | 1,970 | 1,856 | $129K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 7.1% | 1,156 | 1,031 | $117K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 6.4% | 2,469 | 2,194 | $105K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 6.2% | 2,244 | 2,027 | $102K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 2.3% | 777 | 731 | $37K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 1.9% | 742 | 630 | $30K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.7% | 1,151 | 1,078 | $29K |
| 90670 | 1.3% | 2,077 | 1,979 | $21K | |
| 90686 | <1% | 1,224 | 1,105 | $14K |
42 more codes
| 90647 | <1% | 1,264 | $14K | |
| 90723 | <1% | 1,264 | $12K | |
| 99381 | <1% | 226 | $12K | |
| 99173 | <1% | 903 | $12K | |
| 90633 | <1% | 1,018 | $10K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 854 | $10K |
| 90681 | <1% | 893 | $9K | |
| 90697 | <1% | 418 | $6K | |
| 74018 | <1% | 196 | $5K | |
| 87807 | <1% | 420 | $5K | |
| 92551 | <1% | 640 | $5K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 76 | $4K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 96 | $4K |
| 90677 | <1% | 340 | $4K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 833 | $2K |
| 90688 | <1% | 202 | $2K | |
| 90710 | <1% | 161 | $2K | |
| 90707 | <1% | 153 | $2K | |
| 90700 | <1% | 146 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 140 | $2K |
| 90685 | <1% | 156 | $1K | |
| 90716 | <1% | 129 | $1K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 31 | $1K |
| 71045 | Radiologic examination, chest; single view | <1% | 58 | $1K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 31 | $1K |
| 90696 | <1% | 104 | $1K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 50 | $1K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 466 | $1K |
| 90656 | <1% | 95 | $620.35 | |
| 71020 | <1% | 15 | $486.20 | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 14 | $425.43 |
| T1502 | Administration of oral, intramuscular and/or subcutaneous medication by health care agency/professional, per visit | <1% | 230 | $353.60 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 99 | $253.44 |
| 96127 | <1% | 101 | $235.46 | |
| 90651 | <1% | 16 | $183.96 | |
| 90734 | <1% | 14 | $157.68 | |
| 90381 | <1% | 13 | $144.54 | |
| 81003 | <1% | 71 | $140.80 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 32 | $52.67 |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 0% | 47 | $0.00 |
| 90687 | 0% | 13 | $0.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKING, RACHEL (PRESIDENT)